{
  "doc_id": "IPT_50-2022-Tecentriq",
  "created_date": "2022",
  "country": "ES",
  "source_type": "hta_submission",
  "chunks": [
    {
      "heading": "",
      "text": "PROCESSING REPORT THERAPÉUT PT/V1/50/2022 Ter Positioning Report (Tecentriq®) in combination with hepatocellular carcinoma Publication date: June 07, 2022 INTRODUCTION Hepatocellular carcinoma (CHC) is considered one of the most important causes of morbidity and mortality worldwide, drastically influencing patients' vital prognosis. According to the latest data available, globally, CHC is ranked seventh in incidence and fourth in direct cancer mortality (1). The incidence of CHC increases with age (exceptionally occurring before age 40 and median age at the time of diagnosis in our environment is 65-70 years), being more frequent in men than in women (2). The highest incidence rate occurs in Africa and East-East Asia, where the main etiological factors are aflatoxins and chronic infection by Hepatitis B Virus (HB). In Europe, Oceania and America,",
      "start_page": 1,
      "end_page": 11
    },
    {
      "heading": "global (A) and survival",
      "text": "tion in: EJMoa1915745/suppl_file/ne ncia free of progression (B) (15, e.g.1915745_appendix.pdf (Access Mayo",
      "start_page": 11,
      "end_page": 11
    },
    {
      "heading": "(B)",
      "text": "Permanent Commission of REvalM Perman Committee F Table 4. Extraction and expression of results on efficacy parameters of the pivotal study IMbrave150 (A) Primary objectives Efficacy analysis Primary variables Atezolizumab-Sorafenib Overall survival (SG) (time bevacizumab HR (95% CI) p (N=165) from randomization to (N=336) death by any cause) Number of deaths, n (%) 96 (28.6) 65 (39.4) 0.58 (0.42-0.79)a P<0.001 Median OS in months (CI 95%) NA 13.2 (10.4-NA) Atezolizumab-Sorafenib bevacizumab RAR (95% CI) p (N=165) (N=336) Mean rate of overall survival at 6 months, % (95% CI) Average rate of overall survival at 12 months, % (95% CI) Free survival of progression (SLP) (time from RECzolizumab-So HRrafenib36) Number 0,00 % (95% CI) Total survival rate at 12 months, 95% (CI 95%)",
      "start_page": 12,
      "end_page": 16
    },
    {
      "heading": "table under heating <none>",
      "text": "Row 1: Bevacizumab is a humanized monoclonal antibody Row 2: produced by DNA-recombinant technology in Row 3 cells, Chinese hamster ovarian, anti-ligating factor.",
      "start_page": 2,
      "end_page": 2
    },
    {
      "heading": "table under heating <none>",
      "text": "Row 1: Lee, M. S., Ryoo, B.-Y., Hsu, C.-Het al. Atezolizumab\nRow 2: with or without bevacizumab in unresectable\nRow 3: hepatocellular carcinoma (GO30140): an open-label,\nRow 4: multicentre, phase 1b study. The Lancet Oncology,\nRow 5: 21(6), 808–820.",
      "start_page": 7,
      "end_page": 7
    },
    {
      "heading": "table under heating <none>",
      "text": "Row 1: DIFFERENTIAL CHARACTERISTICS SHARED WITH OTHER SIMILARES ALTERNATIVES Row 2: NameAtezolizumab-bevacizumabLenvatinibSorafenib Row 3: Trade nameTecentriq®-AvastinLenvimaNexavar® Row 4: PresentationIntravenousOralRow 5: Posology1200mg-atezolizumab 15mg/kg-bevacizumab Every three weeks8 mg/24h (weight <60kg) 12mg/24h (weight ≥60kg)400mg/12h Row 6: Indication approved in FT or nonYesYesYes Row 7: Adverse effects (frequency order)Hypertension arterial Fatigue ProteinuriaHypertension Diarrhoea HyporhaSyndrome hand-foot Diarrhoea Blood hypertension Row 8: Use of resourcesNeed by Hospital Medical Day (HDM).In-Hospital AdministrationInpatient Rheugym (inuria)",
      "start_page": 9,
      "end_page": 9
    },
    {
      "heading": "table under heating <none> (column 1)",
      "text": "Row 1: CHARACTERISTICS DIFEREN Row 2: NameAtezolizumab-bev Row 3: Atezolizumab-bev Row 4: Trade nameTecentriq®-Avastin Row 5: PresentationIntravenous Row 6: Posology1200mg-atezolizum 15mg/kg-bevacizum Every three weeks Row 7: Indication approved in FT or non-Yes Row 8: Adverse effects (in order of frequency)Hypertension artery Fatigue Proteinuria Row 9: Use of resourcesHosp Medical Need (HDM).Intrahospital Adm Row 10: Efficacy (according to pivotal studies)Superior a sorafeni IMbrave 150)",
      "start_page": 9,
      "end_page": 9
    },
    {
      "heading": "table under heating <none> (column 2)",
      "text": "Row 1: ANEX stopping the combin is on first line Row 2: Row 3: NCIALS COMPA Row 4: Row 5: Row 6: vacizumab Row 7: ® Row 8: Row 9: mab mab s Row 10: Row 11: al Row 12: pital of Day ministration Row 13: ib (test Row 14: Pagi",
      "start_page": 9,
      "end_page": 9
    },
    {
      "heading": "table under heating <none> (column 3)",
      "text": "Row 1: XO nation atezolizumab-be ea of treatment system Row 2:  Row 3: FOLDING OTHERS Row 4:  Row 5: Lenvatinib Row 6: Lenvatinib Row 7: Lenvima Row 8: Oral Row 9: 8 mg/24h (weight <60 12mg/24h (weight ≥60 Row 10: Yes Row 11: Hypertension Arterial Diarrhoea Hyporexia Row 12: Ambulatori Row 13: No less than sorafen (test REFLECT) Row 14: ina 9 of 16",
      "start_page": 9,
      "end_page": 9
    },
    {
      "heading": "table under heating <none> (column 4)",
      "text": "Row 1: Row 2: Com Row 3: Row 4: Row 5: ALTE Row 6: Row 7: Row 8: Row 9: Row 10: Row 11: 0kg) 0kg) Row 12: Row 13: l Row 14: io Row 15: nib Row 16:",
      "start_page": 9,
      "end_page": 9
    },
    {
      "heading": "table under heating <none> (column 5)",
      "text": "Row 1:  Row 2: RE mission Pe Row 3: umab (study CHC Row 4:  Row 5: ERNATIVES Row 6:  Row 7: Soraf Row 8: Soraf Row 9: Nexa Row 10: Oral Row 11: 400m Row 12: Yes Row 13: Syndr Diarrre Hyper Row 14: Régim Row 15: Supe SHAR Row 16:",
      "start_page": 9,
      "end_page": 9
    },
    {
      "heading": "table under heating <none> (column 6)",
      "text": "Row 1: Row 2: SIMILAR",
      "start_page": 9,
      "end_page": 9
    },
    {
      "heading": "table under heating <none> (column 6)",
      "text": "Row 1: fenib Row 2: fenib Row 3: var® Row 4: Row 5: mg/12h Row 6: Row 7: rome hand-foot blood pressure Row 8: men ambulatory Row 9: error to placebo (RP and Asia-Pacific trial)",
      "start_page": 9,
      "end_page": 9
    },
    {
      "heading": "table under heating <none> (column 2)",
      "text": "Row 1: teeth in the pivotal study IMbrav Row 2: Row 3: Page 10 of 16",
      "start_page": 10,
      "end_page": 10
    },
    {
      "heading": "table under heating <none> (column 3)",
      "text": "Row 1: Comisi ve150 (15). Row 2: Row 3:",
      "start_page": 10,
      "end_page": 10
    },
    {
      "heading": "table under heating <global ageing (A) and survival> (column 2)",
      "text": "Row 1: global victory (A) and supervivenable in: EJMoa1915745/suppl_file/ne Row 2: Row 3: Row 4: Page 11 of 16",
      "start_page": 11,
      "end_page": 11
    },
    {
      "heading": "table under heading <(B)> (column 2)",
      "text": "Row 1: Row 2: Row 3:",
      "start_page": 12,
      "end_page": 12
    },
    {
      "heading": "table under heating <(B)> (column 4)",
      "text": "Row 1: Row 2: Row 3: Page 12 of 16",
      "start_page": 12,
      "end_page": 12
    },
    {
      "heading": "table under heading <(B)> (column 7)",
      "text": "Row 1: Row 2: Comisi Row 3: Row 4: Row 5:",
      "start_page": 12,
      "end_page": 12
    },
    {
      "heading": "table under hearing <(B)> (from previous page)",
      "text": "Row 1: Efficacy analysis Row 2: Primary variablesAtezolizumab-bevacizumab (N=336)Sorafenib (N=165)pNNT (CI 95%) Row 3:  Row 4: Global survival (SG) (timeHR (CI 95%) Row 5: from randomisation to  Row 6: failure by any cause) Row 7: Number of deaths, n (%)96 (28.6)65 (39.4)0.58 (0.42-0.79)aP <0.0017 (5-15) Row 8: Median OS in months (IC 95%)NA13.2 (10.4-NA) Row 9: Atezolizumab-Sorafenib (N=165)pNNT (IC95) Row 10: bevacizumabRAR (IC 95%) Row 11: (N=336) Row 12: Mean overall survival ratio at 6 months, % (95%), ,45% (IC 95%, ,45% (IC 95%), ,45% (IC)",
      "start_page": 13,
      "end_page": 13
    },
    {
      "heading": "table under hearing <(B)> (from previous page)",
      "text": "Row 1: Atezolizumab- Row 2: bevacizumab Row 3: (N=336)",
      "start_page": 13,
      "end_page": 13
    },
    {
      "heading": "table under hearing <(B)> (from previous page)",
      "text": "Row 1: Sorafenib Row 2: (N=165)",
      "start_page": 13,
      "end_page": 13
    },
    {
      "heading": "table under hearing <(B)> (from previous page)",
      "text": "Row 1: NNT (IC Row 2: 95%)",
      "start_page": 13,
      "end_page": 13
    },
    {
      "heading": "table under hearing <(B)> (from previous page)",
      "text": "Row 1: Sorafenib Row 2: (N=165)",
      "start_page": 13,
      "end_page": 13
    },
    {
      "heading": "table under hearing <(B)> (from previous page)",
      "text": "Row 1: Atezolizumab- Row 2: bevacizumab Row 3: (N=336)",
      "start_page": 13,
      "end_page": 13
    },
    {
      "heading": "table under hearing <(B)> (from previous page)",
      "text": "Row 1: Sorafenib Row 2: (N=165)",
      "start_page": 13,
      "end_page": 13
    },
    {
      "heading": "table under hearing <(B)> (from previous page)",
      "text": "Row 1: NNT (IC Row 2: 95%)",
      "start_page": 13,
      "end_page": 13
    },
    {
      "heading": "table under hearing <(B)> (from previous page)",
      "text": "Row 1: Efficacy analysis Row 2: Efficacy parametersAtezolizumab-bevacizumabSorafenib Row 3: Secondary variables(N=336)(N=165) Row 4: Objective response rate (percentage of patients with partial or complete response) Row 5: Objective response rate, % (95% CI) according to criteria RECIST 1.127,3 (22.5-32.5)11,9 (7.4-18,0) Row 6: PP<0.001 Row 7: Objective response rate, % (95% CI) according to criteria Mrecist33,2 (28,1-38,6)13,3 (8,4-19,6) Row 8: PP<0.001 Row 9:  Response duration (time from partial or complete response to progression of disease or éxitus) Row 10: Percentage of patients with response duration >6 months, %87,659,1 Row 11: Total quality of life (0,0 times from partial or complete response to  (3% to ) to progression of disease (3% CIQ)",
      "start_page": 13,
      "end_page": 13
    },
    {
      "heading": "table under heating <(B)> (from previous page, column 1)",
      "text": "Row 1: Efficacy analysis Row 2: Primary variablesAtezolizumab-bevacizumab (N=336)Sorafenib (N=165)p Row 3:  Row 4: Overall survival (SG) (timeHR (95% CI) Row 5: from randomisation to  Row 6: failure for any cause) Row 7: Number of deaths, n (%)96 (28.6)65 (39.4)0.58 (0.42-0.79)aP<0.001 Row 8: Median OS in months (IC 95%)NA13,2 (10.4-NA) Row 9: Atezolizumab-Sorafenib (N=165)p Row 10: bevacizumabRAR (IC 95%) Row 11: (N=336) Row 12: Mean survival at 6 months, % (95% CI)84,4 (80,9-88,70.0072,2 (65-73),2",
      "start_page": 13,
      "end_page": 13
    },
    {
      "heading": "table under heating <(B)> (from previous page, column 1)",
      "text": "Row 1: Efficacy analysis Row 2: Efficacy parametersAtezolizumab-bevacizumabSorafen Row 3: Secondary variables(N=336)(N=165 Row 4: Objective response rate (percentage of patients with partial or complete response) Row 5: Objective response rate, % (95% CI) according to criteria RECIST 1.127.3 (22,5-32.5)11.9 (7.4-1 Row 6: P valueP<0.001 Row 7: Objective response rate, % (95% CI) according to criteria Mrecist33,2 (28.1-38,6)13,3 (8,4-1 Row 8: P valueP<0.001 Row 9: Responsive duration (time from partial or complete response to disease progression or éxitus) Row 10: Percentage of patients with response duration >6 months, % Ra87,659,1 Row 11: Defect of patient quality of life (based on full quality of test EORTQLQ0–C30)",
      "start_page": 13,
      "end_page": 13
    },
    {
      "heading": "table under heating <(B)> (from previous page, column 2)",
      "text": "Row 1:  Row 2: NNT (95% CI) Row 3: 7 (5-15) Row 4:  Row 5: NNT (IC95) Row 6: 8(5-24) Row 7: 8 (5-28) Row 8: NNT (95% CI) Row 9: 15 (4-10) Row 10:",
      "start_page": 13,
      "end_page": 13
    },
    {
      "heading": "table under heating <(B)> (from previous page, column 2)",
      "text": "Row 1:  Row 2: nib Row 3: 5) Row 4:  Row 5: 18,0) Row 6:  Row 7: 19,6) Row 8:  Row 9:  Row 10:  Row 11:  Row 12: 7,0) Row 13:  Row 14: 6,2) Row 15:  Row 16: 6,2) Row 17:",
      "start_page": 13,
      "end_page": 13
    },
    {
      "heading": "table under hearing <(B)> (from previous page)",
      "text": "Row 1:  Row 2:  Row 3:  Row 4:",
      "start_page": 14,
      "end_page": 14
    },
    {
      "heading": "table under heating <(B)> (from previous page, column 1)",
      "text": "Row 1:  Row 2:  Row 3:",
      "start_page": 14,
      "end_page": 14
    },
    {
      "heading": "table under heating <(B)> (from previous page, column 2)",
      "text": "Row 1: Row 2: Row 3:",
      "start_page": 14,
      "end_page": 14
    },
    {
      "heading": "table under heating <(B)> (from previous page, column 2)",
      "text": "Row 1: global victory (A) and sup Row 2: Row 3:",
      "start_page": 14,
      "end_page": 14
    },
    {
      "heading": "table under heating <(B)> (from previous page, column 3)",
      "text": "Row 1: Perviv Row 2: Row 3:",
      "start_page": 14,
      "end_page": 14
    },
    {
      "heading": "table under heating <(B)> (from previous page, column 4)",
      "text": "Row 1: Winning Progress Free Row 2: Row 3: Page 14 of 16",
      "start_page": 14,
      "end_page": 14
    },
    {
      "heading": "table under heating <(B)> (from previous page, column 5)",
      "text": "Row 1: sion (B) of estu Row 2: Row 3:",
      "start_page": 14,
      "end_page": 14
    },
    {
      "heading": "table under heating <(B)> (from previous page, column 6)",
      "text": "Row 1: Row 2: Row 3: udio pivotal Imbra Row 4: Row 5:",
      "start_page": 14,
      "end_page": 14
    },
    {
      "heading": "table under heating <(B)> (from previous page, column 2)",
      "text": "Row 1: Adverse cough of study GO30140 (20). Row 2: Row 3: Secondary cough of study IMbrave150 (15). Row 4: Row 5: unit Page 15 of 16",
      "start_page": 15,
      "end_page": 15
    },
    {
      "heading": "table under heating <(B)> (from previous page, column 3)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5:",
      "start_page": 15,
      "end_page": 15
    },
    {
      "heading": "table under heating <(B)> (from previous page, column 6)",
      "text": "Row 1: Row 2: Comisi Row 3: Row 4: Row 5: Row 6: Row 7:",
      "start_page": 15,
      "end_page": 15
    },
    {
      "heading": "table under heating <(B)> (from previous page, column 2)",
      "text": "Row 1: orithm diagnosis Row 2: Row 3: Row 4: unity Row 5:",
      "start_page": 16,
      "end_page": 16
    },
    {
      "heading": "table under heating <(B)> (from previous page, column 3)",
      "text": "Row 1: Nostic of Carcinus Row 2: Row 3:",
      "start_page": 16,
      "end_page": 16
    },
    {
      "heading": "table under heating <(B)> (from previous page, column 4)",
      "text": "Row 1: hepatocellular oma (22) Row 2: Row 3: Page 16 of 16",
      "start_page": 16,
      "end_page": 16
    },
    {
      "heading": "table under heating <(B)> (from previous page, column 5)",
      "text": "Row 1:). Row 2: Row 3:",
      "start_page": 16,
      "end_page": 16
    },
    {
      "heading": "table under heating <(B)> (from previous page, column 6)",
      "text": "Row 1: Row 2: Row 3:",
      "start_page": 16,
      "end_page": 16
    },
    {
      "heading": "table under heating <(B)> (from previous page, column 8)",
      "text": "Row 1: Row 2: Comisi Row 3: Row 4: Row 5:",
      "start_page": 16,
      "end_page": 16
    }
  ]
}